Definium Therapeutics, Inc. (DFTX) stock analysis

In our weekly check, Definium Therapeutics, Inc. is graded F (A to F). Of 19 checks on debt, profit, cash flow and trend: 6 pass, warnings: 1, red flags: 12.

About Definium Therapeutics, Inc.

Definium Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DFTX.

What our checks show for DFTX

Red flags

Warning signs

Strengths

Similar companies

TNGX · ADPT · CRSP · RLAY · IONS · XENE

Questions

What grade does Definium Therapeutics, Inc. (DFTX) have?

In our weekly check, Definium Therapeutics, Inc. is graded F (A to F). Of 19 checks on debt, profit, cash flow and trend: 6 pass, warnings: 1, red flags: 12. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of DFTX stock?

This week's biggest flags for Definium Therapeutics, Inc.: Weak interest cover, Weak EPS forecast, Margins expected to shrink. In total 13 of 19 checks show a warning or a red flag.

What does Definium Therapeutics, Inc. do?

Definium Therapeutics, Inc. is a Healthcare company (Biotechnology) based in the United States, listed on NASDAQ as DFTX.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-11-14

Open the full analysis